Delhi High Court Raises Alarm Over Misuse of Anti‑Diabetic Drugs for Weight Loss

The Delhi High Court expressed serious concern over the unregulated promotion and sale of anti-diabetic drugs like Ozempic (Semaglutide), Mounjaro (Tirzepatide), and Victoza (Liraglutide) for weight loss, including over-the-counter sales, gym prescriptions, and influencer-driven marketing.

These drugs, meant for Type 2 Diabetes, are being sold over the counter, often without prescriptions. 

The Court directed the Central Drugs Standard Control Organisation (CDSCO) to respond within three months to a PIL by Jitendra Chouksey, highlighting risks such as pancreatitis, cardiovascular issues, and threats to reproductive health due to off-label use.

The court warned gyms prescribing these drugs as a “magic formula” and flagged online promotions targeting youth. The case remains open pending regulatory action. (Jitendra Chouksey v. Union of India)